Vibriocidal antibody responses to a bivalent killed whole-cell oral cholera vaccine in a phase III trial in Kolkata, India.
During the development of a vaccine, identification of the correlates of protection is of paramount importance for establishing an objective criterion for the protective performance of the vaccine. However, the ascertainment of correlates of immunity conferred by any vaccine is a difficult task.Whil...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4011749?pdf=render |
| _version_ | 1828866015392432128 |
|---|---|
| author | Suman Kanungo Anna Lena Lopez Mohammad Ali Byomkesh Manna Deok Ryon Kim Tanmay Mahapatra Jan Holmgren Mandeep S Dhingra Thomas F Weirzba G Balakrish Nair Sujit K Bhattacharya John D Clemens Dipika Sur |
| author_facet | Suman Kanungo Anna Lena Lopez Mohammad Ali Byomkesh Manna Deok Ryon Kim Tanmay Mahapatra Jan Holmgren Mandeep S Dhingra Thomas F Weirzba G Balakrish Nair Sujit K Bhattacharya John D Clemens Dipika Sur |
| author_sort | Suman Kanungo |
| collection | DOAJ |
| description | During the development of a vaccine, identification of the correlates of protection is of paramount importance for establishing an objective criterion for the protective performance of the vaccine. However, the ascertainment of correlates of immunity conferred by any vaccine is a difficult task.While conducting a phase three double-blind, cluster-randomized, placebo-controlled trial of a bivalent killed whole-cell oral cholera vaccine in Kolkata, we evaluated the immunogenicity of the vaccine in a subset of participants. Randomly chosen participants (recipients of vaccine or placebo) were invited to provide blood samples at baseline, 14 days after the second dose and one year after the first dose. At these time points, serum geometric mean titers (GMT) of vibriocidal antibodies and seroconversion rates for vaccine and placebo arms were calculated and compared across the age strata (1 to 5 years, 5 to 15 years and more than 15 years) as well as for all age groups.Out of 137 subjects included in analysis, 69 were vaccinees and 68 received placebo. There were 5•7 and 5•8 geometric mean fold (GMF) rises in titers to Vibrio cholerae Inaba and Ogawa, respectively at 14 days after the second dose, with 57% and 61% of vaccinees showing a four-fold or greater titer rise, respectively. After one year, the titers to Inaba and Ogawa remained 1•7 and 2•8 fold higher, respectively, compared to baseline. Serum vibriocidal antibody response to V. cholerae O139 was much lower than that to Inaba or Ogawa. No significant differences in the GMF-rises were observed among the age groups.The reformulated oral cholera vaccine induced a statistically significant anti-O1 Inaba and O1 Ogawa vibriocidal antibody response 14 days after vaccination, which although declined after one year remained significantly higher than baseline. Despite this decline, the vaccine remained protective five years after vaccination. |
| first_indexed | 2024-12-13T04:42:30Z |
| format | Article |
| id | doaj.art-0f99e47eaf4748f28a4ef9af80e52b4e |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-13T04:42:30Z |
| publishDate | 2014-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-0f99e47eaf4748f28a4ef9af80e52b4e2022-12-21T23:59:16ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0195e9649910.1371/journal.pone.0096499Vibriocidal antibody responses to a bivalent killed whole-cell oral cholera vaccine in a phase III trial in Kolkata, India.Suman KanungoAnna Lena LopezMohammad AliByomkesh MannaDeok Ryon KimTanmay MahapatraJan HolmgrenMandeep S DhingraThomas F WeirzbaG Balakrish NairSujit K BhattacharyaJohn D ClemensDipika SurDuring the development of a vaccine, identification of the correlates of protection is of paramount importance for establishing an objective criterion for the protective performance of the vaccine. However, the ascertainment of correlates of immunity conferred by any vaccine is a difficult task.While conducting a phase three double-blind, cluster-randomized, placebo-controlled trial of a bivalent killed whole-cell oral cholera vaccine in Kolkata, we evaluated the immunogenicity of the vaccine in a subset of participants. Randomly chosen participants (recipients of vaccine or placebo) were invited to provide blood samples at baseline, 14 days after the second dose and one year after the first dose. At these time points, serum geometric mean titers (GMT) of vibriocidal antibodies and seroconversion rates for vaccine and placebo arms were calculated and compared across the age strata (1 to 5 years, 5 to 15 years and more than 15 years) as well as for all age groups.Out of 137 subjects included in analysis, 69 were vaccinees and 68 received placebo. There were 5•7 and 5•8 geometric mean fold (GMF) rises in titers to Vibrio cholerae Inaba and Ogawa, respectively at 14 days after the second dose, with 57% and 61% of vaccinees showing a four-fold or greater titer rise, respectively. After one year, the titers to Inaba and Ogawa remained 1•7 and 2•8 fold higher, respectively, compared to baseline. Serum vibriocidal antibody response to V. cholerae O139 was much lower than that to Inaba or Ogawa. No significant differences in the GMF-rises were observed among the age groups.The reformulated oral cholera vaccine induced a statistically significant anti-O1 Inaba and O1 Ogawa vibriocidal antibody response 14 days after vaccination, which although declined after one year remained significantly higher than baseline. Despite this decline, the vaccine remained protective five years after vaccination.http://europepmc.org/articles/PMC4011749?pdf=render |
| spellingShingle | Suman Kanungo Anna Lena Lopez Mohammad Ali Byomkesh Manna Deok Ryon Kim Tanmay Mahapatra Jan Holmgren Mandeep S Dhingra Thomas F Weirzba G Balakrish Nair Sujit K Bhattacharya John D Clemens Dipika Sur Vibriocidal antibody responses to a bivalent killed whole-cell oral cholera vaccine in a phase III trial in Kolkata, India. PLoS ONE |
| title | Vibriocidal antibody responses to a bivalent killed whole-cell oral cholera vaccine in a phase III trial in Kolkata, India. |
| title_full | Vibriocidal antibody responses to a bivalent killed whole-cell oral cholera vaccine in a phase III trial in Kolkata, India. |
| title_fullStr | Vibriocidal antibody responses to a bivalent killed whole-cell oral cholera vaccine in a phase III trial in Kolkata, India. |
| title_full_unstemmed | Vibriocidal antibody responses to a bivalent killed whole-cell oral cholera vaccine in a phase III trial in Kolkata, India. |
| title_short | Vibriocidal antibody responses to a bivalent killed whole-cell oral cholera vaccine in a phase III trial in Kolkata, India. |
| title_sort | vibriocidal antibody responses to a bivalent killed whole cell oral cholera vaccine in a phase iii trial in kolkata india |
| url | http://europepmc.org/articles/PMC4011749?pdf=render |
| work_keys_str_mv | AT sumankanungo vibriocidalantibodyresponsestoabivalentkilledwholecelloralcholeravaccineinaphaseiiitrialinkolkataindia AT annalenalopez vibriocidalantibodyresponsestoabivalentkilledwholecelloralcholeravaccineinaphaseiiitrialinkolkataindia AT mohammadali vibriocidalantibodyresponsestoabivalentkilledwholecelloralcholeravaccineinaphaseiiitrialinkolkataindia AT byomkeshmanna vibriocidalantibodyresponsestoabivalentkilledwholecelloralcholeravaccineinaphaseiiitrialinkolkataindia AT deokryonkim vibriocidalantibodyresponsestoabivalentkilledwholecelloralcholeravaccineinaphaseiiitrialinkolkataindia AT tanmaymahapatra vibriocidalantibodyresponsestoabivalentkilledwholecelloralcholeravaccineinaphaseiiitrialinkolkataindia AT janholmgren vibriocidalantibodyresponsestoabivalentkilledwholecelloralcholeravaccineinaphaseiiitrialinkolkataindia AT mandeepsdhingra vibriocidalantibodyresponsestoabivalentkilledwholecelloralcholeravaccineinaphaseiiitrialinkolkataindia AT thomasfweirzba vibriocidalantibodyresponsestoabivalentkilledwholecelloralcholeravaccineinaphaseiiitrialinkolkataindia AT gbalakrishnair vibriocidalantibodyresponsestoabivalentkilledwholecelloralcholeravaccineinaphaseiiitrialinkolkataindia AT sujitkbhattacharya vibriocidalantibodyresponsestoabivalentkilledwholecelloralcholeravaccineinaphaseiiitrialinkolkataindia AT johndclemens vibriocidalantibodyresponsestoabivalentkilledwholecelloralcholeravaccineinaphaseiiitrialinkolkataindia AT dipikasur vibriocidalantibodyresponsestoabivalentkilledwholecelloralcholeravaccineinaphaseiiitrialinkolkataindia |